BioDelivery Sciences International, Inc.  

(Public, NASDAQ:BDSI)   Watch this stock  
Find more results for BDSI
2.80
0.00 (0.00%)
Sep 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.65 - 2.83
52 week 1.50 - 3.60
Open 2.80
Vol / Avg. 267,566.00/439,025.00
Mkt cap 155.33M
P/E 244.54
Div/yield     -
EPS 0.01
Shares 55.48M
Beta 1.04
Inst. own 43%
Nov 7, 2017
Q3 2017 BioDelivery Sciences International Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Oct 9, 2017
Dar Es Salaam Investment Bank PJSC Annual Shareholders Meeting (Estimated) - 3:00AM EDT - Add to calendar
Sep 26, 2017
BioDelivery Sciences International Inc at Ladenburg Thalmann Healthcare Conference - 3:00PM EDT - Add to calendar
Sep 25, 2017
BioDelivery Sciences International Inc at Cantor Fitzgerald Global Healthcare Conference - 8:00AM EDT - Add to calendar
Sep 12, 2017
BioDelivery Sciences International Inc at Rodman & Renshaw Global Investment Conference
Aug 9, 2017
Q2 2017 BioDelivery Sciences International Inc Earnings Call - Webcast
Aug 9, 2017
Q2 2017 BioDelivery Sciences International Inc Earnings Release
Jun 30, 2017
BioDelivery Sciences International Inc Annual Shareholders Meeting (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -170.16% -431.87%
Operating margin -148.52% -411.26%
EBITD margin - -402.21%
Return on average assets -58.57% -86.58%
Return on average equity -185.10% -957.27%
Employees 99 -
CDP Score - -

Address

4131 Parklake Ave Ste 225
RALEIGH, NC 27612-2390
United States - Map
+1-919-5829050 (Phone)
+1-919-5829051 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

Officers and directors

Frank E. O'Donnell Jr., M.D. Executive Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Mark A. Sirgo Vice Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ernest R. De Paolantonio CPA Chief Financial Officer, Treasurer, Secretary
Age: 63
Bio & Compensation  - Reuters
Niraj Vasisht Ph.D. Senior Vice President of Product Development and Chief Technical Officer
Age: 52
Bio & Compensation  - Reuters
Peter L. Ginsberg Vice President - Business Development
Bio & Compensation  - Reuters
William B. Stone Lead Independent Director
Age: 73
Bio & Compensation  - Reuters
Timothy C. Tyson Director
Age: 62
Bio & Compensation  - Reuters
Charles J. Bramlage Independent Director
Age: 55
Bio & Compensation  - Reuters
Thomas W. D'Alonzo Independent Director
Age: 72
Bio & Compensation  - Reuters
Barry I. Feinberg M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters